title: Nephron sparing surgery is a feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from a single center.
abstract: OBJECTIVE
  Renal cell carcinoma in a renal graft is a rare condition whose incidence will increase in the future. To our knowledge no standardized treatment has been established for this disease. We performed a prospective study of nephron sparing surgery for small renal cell carcinoma in renal grafts.
  
  
  METHODS
  From January 2002 to December 2006, 2,050 renal graft recipients were followed at our transplantation center. Of these patients 7 were diagnosed with histologically confirmed renal cell carcinoma in the renal graft, 5 of whom presented with T1a renal cell carcinoma and prospectively underwent nephron sparing surgery.
  
  
  RESULTS
  Five patients with 15 to 30 mm (median 20) renal cell carcinoma were included in the study and were treated with nephron sparing surgery. Median operative time was 110 minutes (range 60 to 150). Blood loss was less than 200 ml in each case. All tumors were pT1aN0M0 with negative margins. No postoperative complications were observed (hemorrhage, urinary fistulas, renal failure). Preoperative immunosuppressive treatment was not modified postoperatively. At 3 months after nephron sparing surgery and at a mean of 17.4 months of followup (range 5 to 54) no significant impairment of renal function or recurrence was observed.
  
  
  CONCLUSIONS
  Nephron sparing surgery is a safe and efficient procedure for the treatment of renal cell carcinoma in renal grafts, resulting in the preservation of renal function and in short-term cancer control.
authors.affiliation: Department of Urology, Paris 7 University Saint-Louis Hospital, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Chambade
authors.forename: P
authors.initials: P
authors.lastname: Meria
authors.forename: E
authors.initials: E
authors.lastname: Tariel
authors.forename: J
authors.initials: J
authors.lastname: Vérine
authors.forename: E
authors.initials: E
authors.lastname: De Kerviler
authors.forename: M N
authors.initials: MN
authors.lastname: Peraldi
authors.forename: D
authors.initials: D
authors.lastname: Glotz
authors.forename: F
authors.initials: F
authors.lastname: Desgrandchamps
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
mesh_terms: D000328:Adult; D001707:Biopsy, Needle; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology / Q000601:surgery*; D006085:Graft Survival; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods*; D009399:Nephrons / Q000601:surgery; D011446:Prospective Studies; D012086:Reoperation; D018570:Risk Assessment; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome